223 related articles for article (PubMed ID: 23929215)
1. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.
Wyspiańska BS; Bannister AJ; Barbieri I; Nangalia J; Godfrey A; Calero-Nieto FJ; Robson S; Rioja I; Li J; Wiese M; Cannizzaro E; Dawson MA; Huntly B; Prinjha RK; Green AR; Gottgens B; Kouzarides T
Leukemia; 2014 Jan; 28(1):88-97. PubMed ID: 23929215
[TBL] [Abstract][Full Text] [Related]
2. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
3. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
4. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
8. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
9. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
11. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia.
Rinaldi CR; Rinaldi P; Alagia A; Gemei M; Esposito N; Formiggini F; Martinelli V; Senyuk V; Nucifora G; Pane F
Blood; 2010 Dec; 116(26):6023-6. PubMed ID: 20861460
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
13. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
15. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
16. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
Lin X; Rice KL; Buzzai M; Hexner E; Costa FF; Kilpivaara O; Mullally A; Soares MB; Ebert BL; Levine R; Licht JD
Leukemia; 2013 Feb; 27(2):344-52. PubMed ID: 22864358
[TBL] [Abstract][Full Text] [Related]
17. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
Patterson-Fortin J; Moliterno AR
Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
[TBL] [Abstract][Full Text] [Related]
19. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
20. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
